Your browser doesn't support javascript.
Trends in effectiveness of inactivated influenza vaccine in children by age groups in seven seasons immediately before the COVID-19 era.
Shinjoh, Masayoshi; Furuichi, Munehiro; Kobayashi, Hisato; Yamaguchi, Yoshio; Maeda, Naonori; Yaginuma, Mizuki; Kobayashi, Ken; Nogayama, Taisuke; Chiga, Michiko; Oshima, Mio; Kuramochi, Yuu; Yamada, Go; Narabayashi, Atsushi; Ookawara, Ichiro; Nishida, Mitsuhiro; Tsunematsu, Kenichiro; Kamimaki, Isamu; Shimoyamada, Motoko; Yoshida, Makoto; Shibata, Akimichi; Nakata, Yuji; Taguchi, Nobuhiko; Mitamura, Keiko; Takahashi, Takao.
  • Shinjoh M; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Department of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: m-shinjo@z2.keio.jp.
  • Furuichi M; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: furuichi-mm@keio.jp.
  • Kobayashi H; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: hkobayashi1201@keio.jp.
  • Yamaguchi Y; Department of Clinical Research, Department of Infection and Allergy, National Hospital Organization Tochigi Medical Center, 1-10-37 Nakatomaturi, Utsunomiya-City, Tochigi 320-8580, Japan. Electronic address: yoyamaguchitochigimc@gmail.com.
  • Maeda N; Department of Pediatrics, National Hospital Organization Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan. Electronic address: naonorimaeda27@gmail.com.
  • Yaginuma M; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka, Kanagawa 254-0065, Japan. Electronic address: yaginumamizuki@keio.jp.
  • Kobayashi K; Department of Pediatrics, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawanishimachi, Kanagawa-ku, Yokohama 221-0855, Kanagawa, Japan. Electronic address: le.petit.oeuf.26@gmail.com.
  • Nogayama T; Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka, Kanagawa 254-0065, Japan. Electronic address: t.nogayama@keio.jp.
  • Chiga M; Department of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka, Toshima-ku, Tokyo 170-8476, Japan. Electronic address: michiko_chiga@tmhp.jp.
  • Oshima M; Department of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, 2-8-1 Minamiohtsuka, Toshima-ku, Tokyo 170-8476, Japan. Electronic address: mio_ooshima@tmhp.jp.
  • Kuramochi Y; Department of Pediatrics, Ota Memorial Hospital, 455-1 Ohshimacho, Ota City, Gunma 273-8585, Japan. Electronic address: ykura123@gmail.com.
  • Yamada G; Department of Pediatrics, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa-shi, Chiba 272-8513, Japan; Department of Pediatrics, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa 210-0013, Japan. Electronic address: yamago.0414time@gmail.com.
  • Narabayashi A; Department of Pediatrics, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa 210-0013, Japan. Electronic address: naraba@keio.jp.
  • Ookawara I; Department of Pediatrics, Japanese Red Cross Shizuoka Hospital, 8-2 Outemachi, Aoi-ku, Shizuoka 420-0853, Japan. Electronic address: ichiro@szrc.org.
  • Nishida M; Department of Pediatrics, Shizuoka City Shimizu Hospital, 1231 Miyakami, Shimizu-ku, Shizuoka-shi, Shizuoka 424-8636, Japan. Electronic address: mitsumed@outlook.jp.
  • Tsunematsu K; Department of Pediatrics, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0061, Japan. Electronic address: ktsune0605@yahoo.co.jp.
  • Kamimaki I; Department of Pediatrics, National Hospital Organization, Saitama Hospital, 2-1 Suwa, Wako-shi, Saitama 351-0102, Japan. Electronic address: kamimaki.isamu.bv@mail.hosp.go.jp.
  • Shimoyamada M; Department of Pediatrics, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama-shi, Saitama 336-0911, Japan. Electronic address: mochikodamochio@yahoo.co.jp.
  • Yoshida M; Department of Pediatrics, Sano Kosei General Hospital, 1728 Horigome-chou, Sano-city, Tochigi 327-8511, Japan. Electronic address: yoshimako0731@yahoo.co.jp.
  • Shibata A; Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, 284-1 Yobe-cho, Ashikaga, Tochigi 326-0843, Japan. Electronic address: helloakimichi@yahoo.co.jp.
  • Nakata Y; Department of Pediatrics, Nippon Koukan Hospital, 1-2-1Koukan-Dori, Kawasaki, Kanagawa 210-0852, Japan. Electronic address: hihiyuji@gmail.com.
  • Taguchi N; Department of Pediatrics, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama, Kanagawa 220-8581, Japan. Electronic address: n-taguchi@keiyu-hospital.com.
  • Mitamura K; Department of Pediatrics, Eiju General Hospital, 2-23-16 Higashiueno, Taito-ku, Tokyo 110-8645, Japan. Electronic address: mitamurakeiko77@gmail.com.
  • Takahashi T; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: ttakahashi@keio.jp.
Vaccine ; 40(22): 3018-3026, 2022 05 11.
Article in English | MEDLINE | ID: covidwho-1783827
ABSTRACT

BACKGROUND:

We have reported the vaccine effectiveness of inactivated influenza vaccine in children aged 6 months to 15 years between the 2013/14 and 2018/19 seasons. Younger (6-11 months) and older (6-15 years old) children tended to have lower vaccine effectiveness. The purpose of this study is to investigate whether the recent vaccine can be recommended to all age groups.

METHODS:

The overall adjusted vaccine effectiveness was assessed from the 2013/14 until the 2020/21 season using a test-negative case-control design based on rapid influenza diagnostic test results. Vaccine effectiveness was calculated by influenza type and by age group (6-11 months, 1-2, 3-5, 6-12, and 13-15 years old) with adjustments including influenza seasons.

RESULTS:

A total of 29,400 children (9347, 4435, and 15,618 for influenza A and B, and test-negatives, respectively) were enrolled. The overall vaccine effectiveness against influenza A, A(H1N1)pdm09, and B was significant (44% [95% confidence interval (CI), 41-47], 63% [95 %CI, 51-72], and 37% [95 %CI, 32-42], respectively). The vaccine was significantly effective against influenza A and B, except among children 6 to 11 months against influenza B. The age group with the highest vaccine effectiveness was 1 to 2 years old with both influenza A and B (60% [95 %CI, 55-65] and 52% [95 %CI, 41-61], respectively). Analysis for the 2020/21 season was not performed because no cases were reported.

CONCLUSIONS:

This is the first report showing influenza vaccine effectiveness by age group in children for several seasons, including immediately before the coronavirus disease (COVID-19) era. The fact that significant vaccine effectiveness was observed in nearly every age group and every season shows that the recent vaccine can still be recommended to children for the upcoming influenza seasons, during and after the COVID-19 era.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / Influenza A Virus, H1N1 Subtype / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Child / Child, preschool / Humans / Infant Language: English Journal: Vaccine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / Influenza A Virus, H1N1 Subtype / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Child / Child, preschool / Humans / Infant Language: English Journal: Vaccine Year: 2022 Document Type: Article